Amanda Van de Poël

Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986)

Kevin Doyle, Hans Lönn, Helena Käck et al. · Journal of Medicinal Chemistry · 2016 · 80 citations · Full text

Drug Target, Clinical Candidate, Pharmacotherapy +19

VACM-1, a cullin gene family member, regulates cellular signaling

Maria A. Burnatowska-Hledin, Ping Zhao, Byron E. Capps et al. · American Journal of Physiology-Cell Physiology · 2000 · 40 citations

VACM-1, a cul-5 gene, inhibits cellular growth by a mechanism that involves MAPK and p53 signaling pathways

Christa Van Dort, Ping Zhao, K. Parmelee et al. · American Journal of Physiology-Cell Physiology · 2003 · 31 citations

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington’s Disease Models

Leticia Toledo‐Sherman, Perla Breccia, Roger Cachope et al. · Journal of Medicinal Chemistry · 2019 · 24 citations · Full text

Genetics, Molecular Biology, Pharmacotherapy +17

Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington’s Disease

Amanda Van de Poël, Leticia Toledo‐Sherman, Perla Breccia et al. · Journal of Medicinal Chemistry · 2021 · 13 citations · Full text